The world’s largest pharmaceuticals market is also the biggest market for Sun Pharma. We have been present in the US since 1996, working with the country’s healthcare system with a focus on generics, branded generics and over-the-counter (OTC) products. We are valued suppliers to the largest wholesalers, distributors, warehousing and non-warehousing chain drugstores and managed care providers. Being a vertically integrated company with a global presence, we have the flexibility to develop and manufacture products in the US as well as at other locations across the world. Our US headquarters are in Cranbury, New Jersey and we have distribution and customer service teams at multiple locations across the country.
Sun Pharma is present in the US through its own legal entities as well as its subsidiary, Taro Pharmaceuticals. Over the last few years, Sun Pharma has made several acquisitions in the US, including Caraco, DUSA Pharmaceuticals and Pharmalucence. Currently, we are market leaders in the generic dermatology sector, with a broad product portfolio for the treatment of Actinic Keratosis, Fungal Infections and Acne. We have strong capabilities in developing complex products and have a robust pipeline of 190 ANDAs, including high value First-to-File (FTF) opportunities.
Sun Pharma’s latest acquisition of a majority interest in Ranbaxy Laboratories Limited (Ranbaxy) and its Ohm Laboratories facilities in the New Jersey makes it the largest Indian pharma company in the US market, with a significantly expanded portfolio of life-saving and enhancing medicines. Sun Pharma and Ranbaxy have similar backgrounds and corporate values, with customer-oriented cultures and research-driven business models. Ranbaxy fits in well with Sun Pharma’s network of companies serving the US healthcare system.
We have built a strong reputation as a company that is market driven, focused on customer service and capable of offering a wide range of affordable pharmaceutical products. We continue to expand our product portfolio in the US market to the benefit of patients, prescribers and other stakeholders in the healthcare system.
Taro markets a broad range of prescription and OTC products. It is a leading manufacturer and supplier of topical dermatologicals , with a growing line of both, topical products and solid dosage formulations mainly used in cardiology and neurology therapies.
DUSA is focused on the development and marketing of dermatology products. DUSA’s flagship product, Levulan® photodynamic therapy (PDT), is a technology platform used in conjunction with its proprietary light source, the BLU-U® Blue Light Photodynamic Therapy Illuminator, for the treatment of minimally to moderately thick Actinic Keratosis of the face or scalp.
Pharmalucence is a manufacturer of non-cytotoxic human injectable pharmaceuticals, in either liquid or lyophilized form. It also specialises in radio pharmaceutical products. Pharmalucence’s 70,000 sq. ft. manufacturing facility is the region's first unit to utilise fully automated and isolated aseptic technology in support of a wide array of needs, from small clinical fills up to full commercial scale production for markets worldwide.
Ohm Laboratories is a manufacturer of prescription and OTC drugs in solid dosage forms. Ohm is also approved to manufacture controlled substances by the US Drug Enforcement Agency (DEA). Its state-of-the-art laboratory, manufacturing and warehousing facilities are capable of handling high-volume products and large batch sizes, while its supply chain efficiency ensures seamless transportation to customer locations. Ohm is a frontrunner in bringing unique product deliveries and complex combinations to the market.
We provide high-quality, affordable medicines trusted by healthcare professionals and patients in over 150 countries of the world. Our presence in 65 key markets around the world is supported by 45 manufacturing facilities, across five continents. We have a multi-cultural workforce, comprising more than 30,000 employees of over 50 nationalities.